Case Report: Management of Recurrent Ovarian Squamous Cell Carcinoma With PD-1 Inhibitor

Xiao-chen Song, Yong-xue Wang, Mei Yu*, Dong-yan Cao and Jia-xin Yang

Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Obstetrics & Gynecologic Diseases, Beijing, China

Malignant transformations, such as ovarian squamous cell carcinoma (SCC) in ovarian mature cystic teratoma (OMCT), are rare tumors. The management of recurrent disease is still a challenge, and the gene mutations involved remain unclear. We herein report a recurrent case of ovarian SCC with a PIK3CA gene variation and immunohistochemical staining of programmed death-ligand 1 (PD-L1) >10%. This patient achieved clinical remission after platinum-based effective chemotherapy and programmed death 1 (PD-1) immunotherapy.

Keywords: recurrence, PD-1 inhibitor, chemotherapy, immunotherapy combined therapy, ovarian squamous cell carcinoma

INTRODUCTION

Malignant transformation, such as ovarian squamous cell carcinoma (SCC) in ovarian mature cystic teratoma (OMCT), is a rare tumor. It exhibits a poor prognosis when diagnosed at advanced stages (1).

The gene mutations involved remain unclear, and the management of recurrent disease is still a challenge.

In recent years, immune checkpoint inhibitors (ICIs) have demonstrated great potential in treating a variety of cancers. To our knowledge, there is only one report in the literature of metastatic SCC arising from OMCT treated with an ICI (2). We herein report a recurrent case of ovarian SCC with a PIK3CA gene variation and immunohistochemical staining of programmed death-ligand 1 (PD-L1) >10%. This patient achieved clinical remission after platinum-based effective chemotherapy and programmed death 1 (PD-1) immunotherapy.

CASE PRESENTATION

A 63-year-old woman (gravida 3, para 1) was referred to our hospital because of lower abdominal discomfort, and ultrasonography revealed an 8.7 * 8.0 cm heterogeneous adnexal mass in June 2018. The tumor markers were cancer antigen 125 (CA125) of 552.5 U/ml (<35) and SCC-associated antigen (ScC-Ag) of 9.4 ng/ml (<1.5). The human papillomavirus (HPV) screen of the cervix was negative before surgery. Due to the malignancy detected in frozen sections during the operation, laparoscopic hysterectomy plus bilateral salpingo-oophorectomy plus omentectomy plus pelvic lymph node dissection was performed. Postoperative pathologic examination indicated left OMCT
with malignant transformation into moderately differentiated SCC. Metastases were not found in any other excised specimen. The stage was IC1 (cyst ruptured when taken out via vagina during operation) according to the International Federation of Gynecology and Obstetrics (FIGO) classification (3). Tumor markers decreased to normal after surgery. Three cycles of platinum-based chemotherapy (Taxol 175 mg/m² D1 and cisplatin 70 mg/m² D1, intravenously every 3 weeks) were given after surgery. Then, the patient received regular follow-up. The patient signed an informed consent that her data would be used for scientific purposes. The hospital’s ethics committee approved this study.

First Recurrence
At 8 months after the last cycle of chemotherapy, serum Scc-Ag was elevated to 4.2 ng/ml, and PET-CT showed elevated uptake of ¹⁸F-fluorodeoxyglucose in pelvic parailiac vessels and the parasigmoid colon. Then, she returned in April 2019. Considering the multiple lesions in the pelvis, external beam radiation therapy (EBRT) (DT: 50 Gy/25 F) was first given to reduce the tumor burden. Subsequently, the patient was given three cycles of cisplatin plus 5-fluorouracil adjuvant chemotherapy (cisplatin 70 mg/m² D1, 5-fluorouracil 1,000 mg/m² D1–D4, intravenously every 3 weeks). Serum Scc-Ag decreased to normal after the first cycle of chemotherapy. The reduction of the tumor was satisfactory (remaining tumor <1 cm) after three cycles of chemotherapy.

Whole-exome sequencing of the patient identified 372 somatic mutation events (Figure 1). A total of 247 (247/372, 66.4%) were nonsynonymous single nucleotide variations, and 5 were disruptive insertion–deletion events. The immunohistochemical staining of tumor tissue was PD-L1-positive (>10%, Figure 2), and the tumor mutational burden was 7.280 muts/Mb. There were mutations in 14 known driver genes, including PIK3CA, IFNGR1, MAPT, RPS6KA4, BMPR2, THBS2, PPP2R5C, CDKN1A, ENDO1D1, BMPR2, FLT2, IGF1R, TLN1, and PARD3. The PIK3CA gene mutation p.H1047L indicated that the patient may benefit from mTOR inhibitors.

After sufficient explanation and obtaining informed consent, the sirolimus oral pill was administered (2 mg per day). The adverse effect was slightly increased plasma transaminase, which recovered to normal after medication treatment. No other side effects were observed. However, at the seventh month of sirolimus, serum Scc-Ag was elevated again.

Second Recurrence
At the seventh month of sirolimus, serum Scc-Ag elevated to 3.7 ng/ml, and CT showed lung metastasis in April 2020 (Figures 3, 4).

**FIGURE 1** | Summary of exome sequencing results of the tumor tissue in this patient displayed as a diagram. Each circle from the outer to inner is as follows: (A) trapping area. (B) Sequencing depth of tumor samples; different colors represent various depths: red ≥ 500, blue ≥ 100, and others are black. (C) Sequencing depth of control group samples. (D) Frequency of somatic mutations and genes related to exonic and splicing mutations: deletion/insertion mutations are blue, missense/nonsense synonymous mutations are red, and all others are black.
Considering the second recurrence of the tumor and given the tumor’s PD-L1 positivity, six cycles of platinum-based chemotherapy (Taxol 175 mg/m² and cisplatin 70 mg/m², intravenously every 3 weeks) plus PD-1 inhibitor (sintilimab injection, 200 mg, intravenously every 3 weeks) were administered after a discussion at the multidisciplinary tumor board. Sintilimab (Tyvyt®, Innoven Biologics Inc., Jiangsu, China) is a humanized monoclonal antibody that blocks the binding of PD-1 receptor to PD-L1 and PD-L2 and has shown efficacy against a wide variety of solid tumors. After six cycles of chemotherapy plus PD-1 inhibitor, the PD-1 inhibitor was administered every 3 weeks. Serum Scn-Ag decreased to normal after the first cycle of chemotherapy. A chest CT scan showed that the lung metastasis nodules were narrowing (Figures 3a–3c) and in June 2021, there were no abnormal lesions (Figures 3a–3c). The pelvic lesions were simultaneously reduced in size. To date, the patient continues on sintilimab at 13
months with stable disease. There has been no evidence of tumor recurrence.

**DISCUSSION AND CONCLUSIONS**

Malignant transformation occurs in 1%–2% of OMCTs, and the majority of these (80%) are SCCs (1). For those patients, prompt diagnosis and individualized treatment are crucial for a better prognosis. Sakuma (4) reported that optimal cytoreductive surgery can bring a mean survival of 14 months, and in suboptimal cases with advanced-stage disease, it is 7.8 months. The current recommendation of postoperative platinum-based chemotherapy in ovarian SCC is related to its activity in ovarian cancer and gynecological SCCs (5). However, to date, the appropriate treatment for patients with recurrent ovarian SCC is still a difficult problem.

This patient had a 7-month progression-free survival (PFS) with sirolimus used as a maintenance treatment after chemotherapy at the first recurrence, and at the second recurrence, she had a PFS of more than 17 months with PD-1 inhibitor therapy. To date, the survival time has been more than 41 months. For this case with a second recurrence, there are several key issues that should be thoroughly discussed. First, the operation may have played a pivotal role as the initial treatment, but its role in the second cytoreductive surgery is uncertain. Second, the cytogenetic abnormalities might precede histological changes, and the increased copy number of PIK3CA and immunohistochemical positive staining for PD-L1 may be correlated with poor PFS. Thus, these abnormalities could be potential therapeutic targets for ovarian SCC, especially ICIs.

There is a rationale for ICI treatment in the management of ovarian cancer. However, the efficacy remains limited with a response rate of 10%–15% (6, 7). This may be due to a low tumor mutational burden and low PD-L1 expression (7). PD-L1 expression has emerged as one of the biomarkers that could predict sensitivity to ICIs (8). There are no data regarding the prevalence of PD-L1 expression in ovarian SCC, but studies of SCC of other primary sites have shown PD-L1 positivity ranging from 33% to 59% in squamous non-small cell lung cancer to 83.7% in cervical cancer (2, 9). In this patient, positive tumor PD-L1 expression (>10%) may be correlated with the responsiveness of ICI therapy.

Several studies have shown that the malignant transformation of OMCTs may be associated with genetic mutations. OMCT-associated SCC has a much higher overall mutational burden and more copy number alterations than OMCT (10). The most frequently altered genes in ovarian SCC were TP53 (80%), PIK3CA (52%), and CDKN2A (44%) (11). PIK3CA is a key oncogene located on chromosome 3, and PIK3CA p.H1047L is a hotspot mutation that lies within the PI3K/PI4K domain of the PIK3CA protein. H1047L confers a gain-of-function effect on the PIK3CA protein, as indicated by the increased phosphorylation of Akt and Mek 1/2, growth factor-independent cell survival, and transformation in cell cultures (12, 13). Mutations of PIK3CA will cause the PI3K enzyme to be continuously activated (14). It has been reported that a key signaling target of PD-1-mediated inhibition is the PI3K–Akt pathway (15, 16), and PD-1 can block the activation of PI3K by recruiting SHP-2 (16). The immune system plays a significant role in ovarian cancer outcomes. Overexpression of the immune checkpoint receptor PD-L1 can lead to inhibition of an effective antitumor immune response (17). It has been reported that humanized monoclonal antibodies targeting PD-1 confer durable antitumor activity with acceptable safety and toxicity in patients with advanced PD-L1-positive ovarian cancer (18). Wu (2) reported the first case of a patient with metastatic SCC arising from OMCT who was successfully treated with pembrolizumab after progressing through platinum-based combination chemotherapy. Here, we present the clinical experience of a woman with recurrent SCC who responded to treatment with chemotherapy and the PD-1 inhibitor.

Because of tumor heterogeneity, gene mutations, which are the basis of targeted therapy in carcinomas with the same histological type, vary from case to case. Currently, personalized cancer medicine has become increasingly important for the treatment of malignancies. In addition to surgery and chemotherapy, targeted therapy could also benefit refractory cases.

In conclusion, this study is the first report indicating measurable responses to combination chemotherapy with immunotherapy in “recurrent” ovarian SCC. When considered with the findings from previous studies, combination treatment, especially immunotherapy, may lead to improved results. Further studies are needed to confirm our preliminary observations.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

**ETHICS STATEMENT**

The hospital Peking Union Medical College Hospital (CAMS) ethics committee approved this study. The patient signed an informed consent that her data would be used for 40 scientific purposes.

**AUTHOR CONTRIBUTIONS**

XS: manuscript writing. MY: protocol development, manuscript revision, and final approval of the version to be published. YW, D-yC, and J-xY: manuscript revision. All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
REFERENCES

1. Li C, Zhang Q, Zhang S, Dong R, Sun C, Qiu C, et al. Squamous Cell Carcinoma Transformation in Mature Cystic Teratoma of the Ovary: A Systematic Review. BMC Cancer (2019) 19:217. doi: 10.1186/s12885-019-5393-y

2. Wu M, Bennett J, Reid P, Fleming G, Kurnit K. Successful Treatment of Squamous Cell Carcinoma Arising From a Presumed Ovarian Mature Cystic Teratoma With Pembrolizumab. Gynecologic Oncol Rep (2021) 37:100837. doi: 10.1016/j.gore.2021.100837

3. Mutch DG, Prat J. 2014 FIGO Staging for Ovarian, Fallopian Tube and Peritoneal Cancer. Gynecologic Oncol (2014) 133:401–4. doi: 10.1016/j.ygyno.2014.04.013

4. Sakuma M, Otsuki T, Yoshinaga K, Utsunomiya H, Nagase S, Takano T, et al. Malignant Transformation Arising From Mature Cystic Teratoma of the Ovary: A Retrospective Study of 20 Cases. Int J Gynecological Cancer Off J Int Gynecological Cancer Soc (2010) 20:766–71. doi: 10.1111/j.1525-7163.2010.01193.x

5. Omura G, Blessing JA, Ehrlich CE, Miller A, Yordan E, Creasman WT, et al. A Randomized Trial of Cyclophosphamide and Doxorubicin With or Without Cisplatin in Advanced Ovarian Carcinoma. A Gynecologic Oncology Group Study. Cancer (1986) 57:1725–30. doi: 10.1002/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J

6. James N, Woodman M, Ribeiro J. Prognostic Immunologic Signatures in Epithelial Ovarian Cancer. Oncogene (2022). doi: 10.1038/d41388-022-0181-5

7. Chardin L, Leary A. Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1 and PD-L1. Front Oncol (2021) 11:795547. doi: 10.3389/fonc.2021.795547

8. Davis A, Patel V. The Role of PD-L1 Expression as a Predictive Biomarker: An Analysis of All US Food and Drug Administration (FDA) Approvals of Immune Checkpoint Inhibitors. J Immunother Cancer (2019) 7:278. doi: 10.1186/s40425-019-0768-9

9. Chung H, Ros W, Delord J, Perets R, Italiano A, Shapira-Frommer R, et al. Infiltration and PD-L1 Expression in Squamous Cell Carcinoma Arising From Mature Cystic Teratoma of the Ovary: A Retrospective Study of 20 Cases. Int J Gynecological Cancer Off J Int Gynecological Cancer Soc (2010) 20:766–71. doi: 10.1111/j.1525-7163.2010.01193.x

10. Cooke SL, Ennis D, Evers L, Dowson S, Chan MY, Paul J, et al. The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma. Clin Cancer Res (2017) 23:7633–40. doi: 10.1158/1078-0432.CCR-17-1789

11. Dogruol T, Tsang YH, Espitia M, Chen F, Chen T, Chong Z, et al. Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations. Cancer Res (2015) 75:5341–54. doi: 10.1158/0008-5472.CAN-15-1654

12. Patsoukis N, Brown J, Petkova V, Liu F, Li L, Boussiotis VA. Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation. Sci Signaling (2012) 5:ra46. doi: 10.1126/scisignal.2002796

13. Boussiotis VA. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. N Engl J Med (2016) 375:1767–78. doi: 10.1056/NEJMra1514296

14. Chardin L, Leary A. Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1 and PD-L1. Front Oncol (2021) 11:795547. doi: 10.3389/fonc.2021.795547

15. Davis A, Patel V. The Role of PD-L1 Expression as a Predictive Biomarker: An Analysis of All US Food and Drug Administration (FDA) Approvals of Immune Checkpoint Inhibitors. J Immunother Cancer (2019) 7:278. doi: 10.1186/s40425-019-0768-9

16. Chardin L, Leary A. Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1 and PD-L1. Front Oncol (2021) 11:795547. doi: 10.3389/fonc.2021.795547

17. Pardoll DM. The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nat Rev Cancer (2012) 12:252–64. doi: 10.1038/nrc3239

18. Varga A, Piha-Paul S, Ott PA, Mehnert JM, Berton-Rigaud D, Morosky A, et al. Pembrolizumab in Patients With Programmed Death Ligand 1-Positive Advanced Ovarian Cancer: Analysis of KEYNOTE-028. Gynecologic Oncol (2019) 152:243–50. doi: 10.1016/j.ygyno.2018.11.017

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Song, Wang, Yu, Cao and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.